Wilson JM, Lin Y, Luo MJ, et al. - Findings of this hypothesis-generating exploratory analysis revealed reduction in several biomarkers associated with cardiovascular risk in patients with type 2 diabetes who received treatment with tirzepatide, a dual GIP and GLP-1 receptor agonist.

• Tirzepatide was shown to dose-dependently reduce HbA1c and body weight in type 2 diabetes patients in a phase 2 trial of once-weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo.

• This post-hoc analysis was conducted to assess additional impacts of tirzepatide on cardiovascular risk factors.

• At 26 weeks, decrease in YKL-40, ICAM-1, leptin, and GDF-15 levels vs baseline was achieved with tirzepatide 10 mg and 15 mg, as well as decrease in YKL-40 and leptin levels vs placebo and dulaglutide.

• Treatment with tirzepatide 15 mg also reduced ICAM-1 levels relative to placebo and dulaglutide, and hsCRP levels vs baseline and placebo, but not dulaglutide.

• Within 4 weeks of tirzepatide 10 mg and 15 mg use, a rapid fall in YKL-40, hsCRP, and ICAM-1 levels was evident, whereas decline in leptin levels was more slow and did not plateau by 26 weeks.